Latest news with #ENCORE
Hamilton Spectator
28-07-2025
- Business
- Hamilton Spectator
‘My hands and feet went numb': 26-year-old Toronto man wins $60M in Lotto 6/49 jackpot
Bocheng Mei wasn't expecting to become a multimillionaire when he picked up a call from an unknown number. The 26-year-old Toronto resident is Ontario's newest lottery winner, taking home the $60 million Lotto 6/49 Gold Ball jackpot from the May 7 draw. His winning ticket was purchased online through , using the site's 'Never Miss a Draw' subscription feature, which automatically enters players in upcoming draws. After seeing various lottery winners on social media and in the news, Mei decided to try his own luck by signing up online for the subscription. 'I do most stuff online, so I picked my own numbers, added ENCORE, and never had to think about it again — because I knew my tickets would be purchased automatically,' Mei said during his winner celebration in Toronto. When OLG tried to reach out to notify him of the prize, a feature of being an account holder on , he had missed the email. Then, he got a call from an unknown number. 'I answered the call, and the person said they were from OLG,' he said. Skeptical of being scammed, Mei began to Google the representative to confirm they were genuine. 'I knew they were really OLG representatives because they didn't ask for any banking information. They just asked me to check my account. That's when I discovered I had a winning ticket, and it said I'd won $60 million! My hands and feet went numb,' he recalled. Still processing the shock, Mei, who works in the software industry, had to attend a work meeting immediately after the call. After wrapping up his workday, the first people he told were his parents. 'I tried to be very calm when I told them I'd won a big prize. They wanted to make sure I wasn't being tricked, but they know I'm always very cautious,' he said. 'I told them they could retire and enjoy life. They were so shocked to hear the news.' It took a few days for reality to sink in. Eventually, he told a small circle of close friends, who were overjoyed. As one of the only people amongst his friends who purchases lottery tickets, Mei joked that he might be starting a trend. Now, with $60 million in his account, Mei says he's taking time to plan his next steps carefully. 'I love to learn, so I want to take advantage of various educational opportunities. I also want to explore different cultures, so that means plenty of travel,' he said, adding that seeing the Aurora Borealis is on his bucket list. He also hopes to buy a home in Toronto and, most importantly, provide for his parents. 'I can now change their lives along with my own,' Mei said. 'I can provide for them now and make so many things happen for all of us that were never possible before.' Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy . This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Want more of the latest from us? Sign up for more at our newsletter page .
CTV News
04-07-2025
- General
- CTV News
Breslau pair win big ENCORE prize
Keith Forget in an undated photo from the OLG. A small bet has paid off big time for two Breslau residents. When Keith Forget and Patricia D'Aoust bought their Lotto Max ticket for the April 22 draw, they paid an extra $1 to add ENCORE. The OLG said they matched six of the seven numbers, in exact order, and won $100,000. Forget and D'Aoust purchased their ticket at the Ministop store on Victoria Street North in Kitchener.
Hamilton Spectator
11-06-2025
- Health
- Hamilton Spectator
Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025
NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) — Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced seven presentations, including two featured oral plenary sessions, on AXS-12 and solriamfetol, at SLEEP 2025, the 39th annual meeting of the Associated Professional Sleep Societies (APSS), being held June 8-11, 2025, in Seattle, Washington. Details for the presentations are as follows: AXS-12 Title: ENCORE: Topline Results of a Phase 3 Open-Label Extension and Randomized-Withdrawal Trial of AXS-12 in Narcolepsy Lead Author: Richard Bogan, MD, FCCP, FAASM, Associate Clinical Professor at the University of South Carolina School of Medicine in Columbia, SC Poster Presentation Date and Time: Wednesday, June 11, 10 - 11:45 a.m. PT Poster Session: P-51 Poster Number: 405 Title: Impact of AXS-12 on Symptom Severity and Functional Impairment in Narcolepsy: Results from the Phase 3 SYMPHONY Trial Lead Author: Michael Thorpy, MD, Director of the Sleep-Wake Disorders Center at the Montefiore Medical Center and Professor of Neurology at Albert Einstein College of Medicine, New York, NY Oral Presentation Date and Time: Wednesday, June 11, 3:45 - 4 p.m. PT Oral Session: O-24 Poster Presentation Date and Time: Wednesday, June 11, 10 - 11:45 a.m. PT Poster Session: P-51 Poster Number: 390 Title: Residual Symptom Burden in Patients with Narcolepsy Satisfied with Treatment: Subgroup Analysis from the CRESCENDO Survey Lead Author: Michael Thorpy, MD, Director of the Sleep-Wake Disorders Center at the Montefiore Medical Center and Professor of Neurology at Albert Einstein College of Medicine, New York, NY Oral Presentation Date and Time: Wednesday, June 11, 4 - 4:15 p.m. PT Oral Session: O-24 Poster Presentation Date and Time: Wednesday, June 11, 10 - 11:45 a.m. PT Poster Session: P-51 Poster Number: 391 Solriamfetol Title: Effects of Solriamfetol on Neuropsychological Outcomes in Patients with Obstructive Sleep Apnea in the Real-World SURWEY Study Lead Author: Yaroslav Winter, MD, Mainz Comprehensive Epilepsy and Sleep Medicine Center, Department of Neurology, Johannes Gutenberg-University, Mainz, Germany Poster Presentation Date and Time: Wednesday, June 11, 10 - 11:45 a.m. PT Poster Session: P-50 Poster Number: 366 Title: Real-World Use of Solriamfetol for Excessive Daytime Sleepiness in Patients with Obstructive Sleep Apnea in the US Lead Author: Yang Zhao, PhD, Axsome Therapeutics Poster Presentation Date and Time: Wednesday, June 11, 10 - 11:45 a.m. PT Poster Session: P-50 Poster Number: 369 About AXS-12 AXS-12 (reboxetine) is a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator under development for the treatment of narcolepsy. AXS-12 is thought to modulate noradrenergic activity to promote maintain tone during wakefulness, and noradrenergic and cortical dopamine signaling to promote wakefulness and enhance cognition. AXS-12 has been granted U.S. Food and Drug Administration (FDA) Orphan Drug Designation for the treatment of narcolepsy. AXS-12 is covered by issued patents providing protection to at least 2039. AXS-12 is an investigational drug product not approved by the FDA. About Solriamfetol Solriamfetol is a dopamine and norepinephrine reuptake inhibitor (DNRI), TAAR1 agonist, and 5-HT1A agonist being developed for the treatment of attention deficit hyperactivity disorder (ADHD), major depressive disorder (MDD), binge eating disorder (BED), and excessive sleepiness associated with shift work disorder (SWD). About Axsome Therapeutics Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, and multiple late-stage development programs addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain's biggest problems so patients and their loved ones can flourish. For more information, please visit us at and follow us on LinkedIn and X . Forward Looking Statements Certain matters discussed in this press release are 'forward-looking statements'. The Company may, in some cases, use terms such as 'predicts,' 'believes,' 'potential,' 'continue,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'intends,' 'may,' 'could,' 'might,' 'will,' 'should' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company's statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company's SUNOSI®, AUVELITY®, and SYMBRAVO® products and the success of the Company's efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company's ability to maintain and expand payer coverage; the success, timing and cost of the Company's ongoing clinical trials and anticipated clinical trials for the Company's current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company's ability to fully fund the Company's disclosed clinical trials, which assumes no material changes to the Company's currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company's ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application ('NDA') for any of the Company's current product candidates; the Company's ability to fund additional clinical trials to continue the advancement of the Company's product candidates; the timing of and the Company's ability to obtain and maintain U.S. Food and Drug Administration ('FDA') or other regulatory authority approval of, or other action with respect to, the Company's product candidates, including statements regarding the timing of any NDA submission; the Company's ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the Company's ability to successfully resolve any intellectual property litigation, and even if such disputes are settled, whether the applicable federal agencies will approve of such settlements; the successful implementation of the Company's research and development programs and collaborations; the success of the Company's license agreements; the acceptance by the market of the Company's products and product candidates, if approved; the Company's anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company's commercial launch of its other product candidates, if approved, and the potential impact on the Company's anticipated cash runway; the Company's ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. Investors: Mark Jacobson Chief Operating Officer (212) 332-3243 mjacobson@ Media: Darren Opland Director, Corporate Communications (929) 837-1065 dopland@
Sassy Mama
11-06-2025
- General
- Sassy Mama
This International School Is Rolling Out 30+ New IB Initiatives: Here's What To Know
If you're on the hunt for the perfect IB programme for your child, check out how GESS' exciting updates can support your child's growth, wellbeing, and future opportunities. For many GESS families, school feels like a second home—so it's no surprise that when changes are on the horizon, they matter. Starting in the Academic Year 2025/26, GESS' IB track will witness thoughtfully designed initiatives, driven by months of feedback from parents, students, and educators. And if you're a parent looking for more tailored learning backed by high-quality teaching and learning, enhanced learner outcomes, and a school that believes in your child's wellbeing, the updates are worth a closer look. New offerings including opportunities for physical activity, creativity & flexibility Parents with children in primary school (ages 6 to 10) can expect a refreshed and well-rounded learning experience. Starting in Grade 1, students will now have the chance to pick up a new language–French, Spanish, or Mandarin–offered at an acquisition level to gently introduce foreign language learning. The outdoor education programme has also been revamped, with three dedicated hours each week for sports and swimming, ensuring kids stay active and engaged. On the creative side, drama will now be part of the curriculum, alongside existing art and music lessons. For middle schoolers aged 11 to 13, the changes are designed to help students explore their interests while receiving personalised support. A new ENCORE electives programme introduces over 25 specialist courses across languages, arts, technology, and sports offered during school hours, so families don't have to juggle too many after-school commitments. The new FLEX programme provides more time for academic support, enrichment activities, clubs, and leadership opportunities. Students will also benefit from smaller homeroom classes of just 12 to 14 students, allowing more tailored wellbeing and guidance. The school day will include more unstructured time to help reduce stress and boost creativity, with an added focus on restorative practices and social-emotional learning. Growing beyond the classroom with innovative learning At GESS, academic excellence doesn't equate to high pressure. The restructure puts student wellbeing at the centre—starting with a calmer, more balanced school day. Parents of high school students (aged 14 to 18) will be glad to know that more academic pathways and future planning resources are now in place. New subject offerings, such as environmental systems & societies and computer science, expand learning opportunities. There's also a new Business and Sustainability Pathway that leads to the globally recognised IB Careers Programme qualification. Students will receive 33% more subject teaching hours, along with expanded access to mentorship, one-on-one tutoring, and counselling. The award-winning BeyondClassrooms initiative is also growing, introducing a new internship programme and industry speaker series, while university guidance and career prep efforts continue to scale up to help students transition smoothly into life beyond school. At its heart, this restructuring is about recognising that every student is different—and creating a school experience that allows them to flourish in their own way. Click here to learn more about GESS' latest enhancements and developments! GESS – International School, 2 Dairy Farm Lane, Singapore 677621, Tel: (+65) 6461 088,
CairoScene
09-06-2025
- Entertainment
- CairoScene
El Mehdi Unleashes His Most Personal Work Yet With New Track ‘ENCORE'
Moroccan artist El Mehdi returns with 'ENCORE', a raw and reflective single blending Amazigh heritage with genre-blurring emotion. Jun 09, 2025 Moroccan artist El Mehdi has dropped ENCORE, a powerful single years in the making. Written during one of the most difficult moments in his life, the track nearly never made it to the light. But now, fully realized and sonically expansive, ENCORE arrives as his most vulnerable and honest offering yet. Built around a haunting arrangement of oud, cello, and violins, the track leans into minimal yet cinematic textures, produced by Sunjun, Tallisker, and Wake Island, with additional vocal production by Caracol. El Mehdi's voice drips with intent, raw, textured, and resolute. The cover art pays homage to his Aït Atta ancestry through Asbia' Iquorain, a set of Amazigh silver bracelets traditionally worn by women for protection and pride. 'They embody the duality I explore in ENCORE,' Mehdi says. 'Our strengths, our weapons, can also become our chains.'
